A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL).

@article{Gertz2002AMP,
  title={A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL).},
  author={Morie A Gertz and Martha Q. Lacy and Angela Dispenzieri and Bruce D Cheson and Bart Barlogie and Robert A Kyle and Giovanni Palladini and Susan Michelle Geyer and Giampaolo Merlini},
  journal={Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis},
  year={2002},
  volume={9 1},
  pages={24-30}
}
INTRODUCTION 4'-Iodo-4'-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results. METHODS Patients with biopsy-proven amyloidosis were required to have a cardiac ejection fraction > 50%, ventricular septal thickness < 20 mm, serum creatinine < 2.5 mg per dL, bilirubin < or = 2.0 mg per dL, neutrophils > 1,500 per microL, and platelets > 100,000 per microL. IDOX was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

Similar Papers

Loading similar papers…